BiotechTV - News Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry
6 snips
Oct 22, 2025 Molly Gibson, Co-founder and CEO of Expedition Medicines, dives into the innovative world of generative covalent small-molecule chemistry. She explains how her company is revolutionizing drug development with a $50 million backing and a partnership with Pfizer to tackle challenging targets like prostate cancer. Listeners will learn about the technology behind covalent chemistry, real-world applications, and the use of AI to generate new drug candidates. Molly also highlights Expedition's unique approach compared to other biotech firms, emphasizing their focus on previously undrugged targets.
AI Snips
Chapters
Transcript
Episode notes
Generative Covalent Design
- Expedition Medicines uses small molecules that form permanent covalent bonds with target proteins.
- Generative algorithms learn rules of covalent bond formation to design molecules with high probability of success.
Platform Integration For Hard Targets
- Expedition's platform combines a novel chemical library, chemoproteomics, generative AI, and quantum chemistry tailored to covalent problems.
- The integration is designed to generalize to targets without prior data and produce first-in medicines.
Proteome-Scale Data Powers Models
- Expedition pairs a chemoproteomics high-throughput engine with AI to generate quantitative, proteome-wide covalent binding data.
- That ground-truth dataset trains foundation models and accelerates scalable drug discovery.